Pandemic Patents: Who Owns the Cure in a Borderless Crisis?
When the next pandemic strikes, the question of who lives and who waits may hinge less on hospital capacity than on the fine print of intellectual property law. Vaccines, antivirals, and monoclonal antibodies can now be developed in record time. But as the world learned in 2020, innovation without access leaves millions unprotected. The scramble for cures in a borderless crisis is no longer just a matter of science—it is a battle over ownership.
Pandemic Patents: Who Owns the Cure in a Borderless Crisis? Read More »










